Cargando…

Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation

Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhaoqiang, Zhang, Zepeng, Liu, Jiaqi, Qi, Hongyu, Li, Jing, Chen, Jinjin, Huang, Qingxia, Liu, Qing, Mi, Jia, Li, Xiangyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084182/
https://www.ncbi.nlm.nih.gov/pubmed/35548468
http://dx.doi.org/10.3389/fcimb.2022.853981
_version_ 1784703555893985280
author Chen, Zhaoqiang
Zhang, Zepeng
Liu, Jiaqi
Qi, Hongyu
Li, Jing
Chen, Jinjin
Huang, Qingxia
Liu, Qing
Mi, Jia
Li, Xiangyan
author_facet Chen, Zhaoqiang
Zhang, Zepeng
Liu, Jiaqi
Qi, Hongyu
Li, Jing
Chen, Jinjin
Huang, Qingxia
Liu, Qing
Mi, Jia
Li, Xiangyan
author_sort Chen, Zhaoqiang
collection PubMed
description Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut microbiota diversity, and gut microbiota could also regulate the transformation of ginsenosides. We conclude the characteristics of ginseng in regulating gut microbiota, as the potential targets to prevent and treat metabolic diseases, colitis, neurological diseases, cancer, and other diseases. Ginseng treatment can increase some probiotics such as Bifidobacterium, Bacteroides, Verrucomicrobia, Akkermansia, and reduce pathogenic bacteria such as Deferribacters, Lactobacillus, Helicobacter against various diseases. Meanwhile, Bacteroides, Eubacterium, and Bifidobacterium were found to be the key bacteria for ginsenoside transformation in vivo. Overall, ginseng can regulate gut microbiome diversity, further affect the synthesis of secondary metabolites, as well as promote the transformation of ginsenosides for improving the absorptivity of ginsenosides. This review can provide better insight into the interaction of ginseng with gut microbiota in multiple disorders and ginsenoside transformation.
format Online
Article
Text
id pubmed-9084182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90841822022-05-10 Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation Chen, Zhaoqiang Zhang, Zepeng Liu, Jiaqi Qi, Hongyu Li, Jing Chen, Jinjin Huang, Qingxia Liu, Qing Mi, Jia Li, Xiangyan Front Cell Infect Microbiol Cellular and Infection Microbiology Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut microbiota diversity, and gut microbiota could also regulate the transformation of ginsenosides. We conclude the characteristics of ginseng in regulating gut microbiota, as the potential targets to prevent and treat metabolic diseases, colitis, neurological diseases, cancer, and other diseases. Ginseng treatment can increase some probiotics such as Bifidobacterium, Bacteroides, Verrucomicrobia, Akkermansia, and reduce pathogenic bacteria such as Deferribacters, Lactobacillus, Helicobacter against various diseases. Meanwhile, Bacteroides, Eubacterium, and Bifidobacterium were found to be the key bacteria for ginsenoside transformation in vivo. Overall, ginseng can regulate gut microbiome diversity, further affect the synthesis of secondary metabolites, as well as promote the transformation of ginsenosides for improving the absorptivity of ginsenosides. This review can provide better insight into the interaction of ginseng with gut microbiota in multiple disorders and ginsenoside transformation. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9084182/ /pubmed/35548468 http://dx.doi.org/10.3389/fcimb.2022.853981 Text en Copyright © 2022 Chen, Zhang, Liu, Qi, Li, Chen, Huang, Liu, Mi and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Chen, Zhaoqiang
Zhang, Zepeng
Liu, Jiaqi
Qi, Hongyu
Li, Jing
Chen, Jinjin
Huang, Qingxia
Liu, Qing
Mi, Jia
Li, Xiangyan
Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title_full Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title_fullStr Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title_full_unstemmed Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title_short Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
title_sort gut microbiota: therapeutic targets of ginseng against multiple disorders and ginsenoside transformation
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084182/
https://www.ncbi.nlm.nih.gov/pubmed/35548468
http://dx.doi.org/10.3389/fcimb.2022.853981
work_keys_str_mv AT chenzhaoqiang gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT zhangzepeng gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT liujiaqi gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT qihongyu gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT lijing gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT chenjinjin gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT huangqingxia gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT liuqing gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT mijia gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation
AT lixiangyan gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation